T_H2-polarized $CD4^+$ T cells and macrophages limit efficacy of radiation therapy

Supplemental Data

Stephen L. Shiao[1], Brian Ruffell[2], David G. DeNardo[3], Bruce A. Faddegon[4], Catherine C. Park[4], Lisa M. Coussens[2,*]

[1]Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048
[2]Department of Cell, Developmental & Cancer Biology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR
[3]Department of Medicine, Department of Pathology and Immunology, and Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110.
[4]Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143

[*]Address for correspondence:
Lisa M. Coussens, Ph.D.
Cell, Developmental & Cancer Biology
Knight Cancer Institute
Oregon Health & Science University
3181 SW Sam Jackson Park Road
Portland, OR 97239-3098
Voice: 503-494-7811
Fax: 503-494-4253
email: coussenl@ohsu.edu

Supplemental Figure Legends

Supplemental Figure 1: Radiation dose response and immune profile. A) Orthotopic MMTV-PyMT-derived explant tumors were grown to a median diameter of 1.0 cm for study enrollment (day 0), and one day later received localized gamma irradiation (2 or 8 Gy). Total tumor burden/animal was then assessed every 3 days until endpoint. Treatment schematic is depicted at top and data are displayed as mean tumor burden ± SEM (>5 mice/group). Significance was determined by two-way ANOVA. One of two experiments is shown. **B)** Number of $CD3^+CD4^+$, $CD3^+CD8^+$, and $CD11b^+F4/80^+$ cells within tumors 14 days following RT in groups that were untreated, treated with RT (2 Gy), RT (5 Gy) or RT (8 Gy). Data are depicted as mean number of cells ± SEM as a % of $CD45^+$ cells as analyzed by flow cytometry (>5 mice/group). Significance was determined by an unpaired t-test relative to untreated controls. For all panels, significance is shown as $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.

Supplemental Figure 2: Immune profile with RT in combination with αCSF-1 mAb or PLX3397. A) Number of $CD3^+CD4^+$, $CD3^+CD8^+$, and $CD11b^+F4/80^+$ cells within tumors 4 days following RT (2 days after administration of αCSF-1 mAb) in groups that were untreated, treated with αCSF-1 mAb alone, RT (5 Gy) alone or treated with a combination of RT and αCSF-1 mAb. **B)** Number of $CD3^+CD4^+$, $CD3^+CD8^+$, and $CD11b^+F4/80^+$ cells within tumors 4 days following RT (2 days after administration of PLX3397) in groups that were untreated, treated with PLX3397 alone, RT (5 Gy) alone or treated with a combination of RT and PLX3397. Data are depicted as mean number of cells ± SEM as a % of $CD45^+$ cells as analyzed by flow cytometry (>5 mice/group). For all figures significance is shown as $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.

Shiao et al., Supplemental Figure 1



Shiao et al, Supplemental Figure 2

A



B